Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.

BACKGROUND Hypertrophic cardiomyopathy is a genetic disease associated with a risk of ventricular tachyarrhythmias and sudden death, especially in young patients. METHODS We conducted a retrospective multicenter study of the efficacy of implantable cardioverter-defibrillators in preventing sudden death in 128 patients with hypertrophic cardiomyopathy who were judged to be at high risk for sudden death. RESULTS At the time of the implantation of the defibrillator, the patients were 8 to 82 years old (mean [+/-SD], 40+/-16), and 69 patients (54 percent) were less than 41 years old. The average follow-up period was 3.1 years. Defibrillators were activated appropriately in 29 patients (23 percent), by providing defibrillation shocks or antitachycardia pacing, with the restoration of sinus rhythm; the average age at the time of the intervention was 41 years. The rate of appropriate defibrillator discharge was 7 percent per year. A total of 32 patients (25 percent) had episodes of inappropriate discharges. In the group of 43 patients who received defibrillators for secondary prevention (after cardiac arrest or sustained ventricular tachycardia), the devices were activated appropriately in 19 patients (11 percent per year). Of 85 patients who had prophylactic implants because of risk factors (i.e., for primary prevention), 10 had appropriate interventions (5 percent per year). The interval between implantation and the first appropriate discharge was highly variable but was substantially prolonged (four to nine years) in six patients. In all 21 patients with stored electrographic data and appropriate interventions, the interventions were triggered by ventricular tachycardia or fibrillation. CONCLUSIONS Ventricular tachycardia or fibrillation appears to be the principal mechanism of sudden death in patients with hypertrophic cardiomyopathy. In high-risk patients with hypertrophic cardiomyopathy, implantable defibrillators are highly effective in terminating such arrhythmias, indicating that these devices have a role in the primary and secondary prevention of sudden death.

[1]  B. Maron,et al.  Hypertrophic Cardiomyopathy Prognostic Value of Systemic Blood Pressure Response During Exercise in a Community-Based Patient Population With Hypertrophic Cardiomyopathy , 2016 .

[2]  P. Elliott,et al.  Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[3]  B. Maron,et al.  Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. , 1999, JAMA.

[4]  B. Maron,et al.  Aborted Sudden Cardiac Death in Hypertrophic Cardiomyopathy , 1999, Journal of cardiovascular electrophysiology.

[5]  Paul J. Wang,et al.  Clinical Profile of Commotio Cordis: An Under Appreciated Cause of Sudden Death in the Young During Sports and Other Activities , 1999, Journal of cardiovascular electrophysiology.

[6]  C. Schuger,et al.  Sudden death in implantable cardioverter-defibrillator recipients: clinical context, arrhythmic events and device responses. , 1999, Journal of the American College of Cardiology.

[7]  S. Hohnloser,et al.  Electrical storm in patients with transvenous implantable cardioverter-defibrillators: incidence, management and prognostic implications. , 1998, Journal of the American College of Cardiology.

[8]  R. Cappato,et al.  Ventricular tachycardia during follow-up in patients resuscitated from ventricular fibrillation: experience from stored electrograms of implantable cardioverter-defibrillators. , 1998, Journal of the American College of Cardiology.

[9]  A. Moss,et al.  Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases:hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. A statement for healthcare professionals from the Councils on Clinical Cardiology, Cardiovascular Disea , 1998, Circulation.

[10]  B. Maron,et al.  Implications of left ventricular remodeling in hypertrophic cardiomyopathy. , 1998, The American journal of cardiology.

[11]  M A Hlatky,et al.  ACC/AHA Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Executive Summary--a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). , 1998, Circulation.

[12]  G. Breithardt,et al.  Is the implantable defibrillator indicated in patients with hypertrophic cardiomyopathy and aborted sudden death? , 1998, Journal of the American College of Cardiology.

[13]  J. Brugada,et al.  Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. , 1998, Journal of the American College of Cardiology.

[14]  A. Schaumann,et al.  Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: a prospective study including 200 patients. , 1998, Circulation.

[15]  Huabin Sun,et al.  The Value of Electrophysiology Study and Prophylactic Implantation of Cardioverter Defibrillator in Patients with Hypertrophic Cardiomyopathy , 1998, Pacing and clinical electrophysiology : PACE.

[16]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[17]  W. Mckenna,et al.  Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. , 1997, Circulation.

[18]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.

[19]  B. Maron,et al.  Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. , 1995, Journal of the American College of Cardiology.

[20]  W. Williams,et al.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment. , 1995, Circulation.

[21]  D. Zipes,et al.  Results of the international study of the implantable pacemaker cardioverter-defibrillator. A comparison of epicardial and endocardial lead systems. The Pacemaker-Cardioverter-Defibrillator Investigators. , 1995, Circulation.

[22]  C. Autore,et al.  Prognosis of Asymptomatic Patients With Hypertrophic Cardiomyopathy and Nonsustained Ventricular Tachycardia , 1994, Circulation.

[23]  M. Silka,et al.  Sudden Cardiac Death and the Use ofImplantable Cardioverter‐Defibrillators in Pediatric Patients , 1993, Circulation.

[24]  W. Mckenna,et al.  The management of hypertrophic cardiomyopathy. , 1997, The New England journal of medicine.

[25]  A. Camm,et al.  Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. , 1989, Circulation.

[26]  A. Castellanos,et al.  Time to first shock and clinical outcome in patients receiving an automatic implantable cardioverter-defibrillator. , 1989, Journal of the American College of Cardiology.

[27]  B. Maron,et al.  Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. , 1989, Journal of the American College of Cardiology.

[28]  K. Peterson,et al.  Hypertrophic cardiomyopathy and sudden death. , 1988, The New England journal of medicine.

[29]  W. Williams,et al.  Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. , 1985, Progress in cardiovascular diseases.

[30]  C. Oakley,et al.  Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. , 1985, British heart journal.

[31]  J. Deanfield,et al.  Hypertrophic cardiomyopathy: an important cause of sudden death. , 1984, Archives of disease in childhood.

[32]  R. Bonow,et al.  Hypertrophic cardiomyopathy. , 1987, Disease-a-month : DM.

[33]  W. Mckenna,et al.  Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. , 1981, The American journal of cardiology.

[34]  V L Gott,et al.  Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. , 1980, The New England journal of medicine.

[35]  W. Roberts,et al.  Quantitative Analysis of Cardiac Muscle Cell Disorganization in the Ventricular Septum of Patients with Hypertrophic Cardiomyopathy , 1979, Circulation.

[36]  D. G. Ritter,et al.  Idiopathic hypertrophic subaortic stenosis in the young. , 1978, The American journal of cardiology.

[37]  W. Roberts,et al.  Asymmetric Septal Hypertrophy in Childhood , 1976, Circulation.

[38]  C. Oakley,et al.  The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. , 1974, Circulation research.

[39]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[40]  D TEARE,et al.  ASYMMETRICAL HYPERTROPHY OF THE HEART IN YOUNG ADULTS , 1958, British heart journal.